Benzinga’s Top Ratings Upgrades, Downgrades For August 1, 2023
Upgrades According to Northcoast Research, the prior rating for Boeing Co (NYSE:BA) was changed from Sell to Neutral.…
Expert Ratings for Chinook Therapeutics
Analysts have provided the following ratings for Chinook Therapeutics (NASDAQ:KDNY) within the last quarter: Bullish Somewhat Bullish Indifferent…
Benzinga’s Top Ratings Upgrades, Downgrades For June 14, 2023
Upgrades MoffettNathanson upgraded the previous rating for Shift4 Payments Inc (NYSE:FOUR) from Market Perform to Outperform. For the…
Benzinga’s Top Ratings Upgrades, Downgrades For June 13, 2023
Upgrades According to Goldman Sachs, the prior rating for Oracle Corp (NYSE:ORCL) was changed from Sell to Neutral.…
Chinook Therapeutics To Present Updated Data From Zigakibart Phase 1/2 Trial In Patients With IgA Nephropathy At The 60th European Renal Association Congress
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with
Nasdaq Gains 1%; US Budget Deficit Widens In May
U.S. stocks traded higher toward the end of trading, with Nasdaq Composite gaining over 100 points on Monday.
The Dow traded up 0.19% to 33,939.74 while the NASDAQ rose 1% to 13,391.54. The S&P 500, also rose, gaining, 0.47% to 4,319.22.
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 58.4% to $13.51 during Monday’s regular session. The current volume of…
Why Asset Entities Shares Are Trading Higher By 142%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Asset Entities Inc. (NASDAQ: ASST) shares jumped 142% to $2.79 after the company announced the development of an AI bot as part of its AE360DDM suite of services on Discord.
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Within the last quarter, Chinook Therapeutics (NASDAQ:KDNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
What To Know About Guggenheim’s Downgrade of Chinook Therapeutics
Guggenheim downgraded its rating of Chinook Therapeutics (NASDAQ:KDNY) to Neutral with a price target of $40.00, changing its…